Ovarian Cancer Clinical Trial
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Summary
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
Eligibility Criteria
Inclusion criteria:
Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin).
Has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol.
Is on a specifically prohibited medication or requires these medications during treatment with GW786034.
Exclusion criteria:
Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy.
Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or higher).
Currently taking warfarin.
Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Atlanta Georgia, 30342, United States
Austin Texas, 78731, United States
Bedford Texas, 76022, United States
Dallas Texas, 75246, United States
Fort Worth Texas, 76104, United States
Randwick New South Wales, 2031, Australia
Herston Queensland, 4029, Australia
Melbourne , 3084, Australia
Singapore , 11907, Singapore
Singapore , 22989, Singapore
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.